OBJECTIVE: Interleukin-10 (IL-10) is a potent inhibitor of the proinflammatory cytokines, including tumor necrosis factor alpha and IL-1, which are considered important in the pathogenesis of rheumatoid arthritis (RA). The study was undertaken to establish whether IL-10 can ameliorate arthritis in the collagen-induced arthritis (CIA) model of RA. METHODS: DBA/1 mice were immunized with bovine type II collagen in adjuvant, and treated daily after disease onset with recombinant murine IL-10 or with saline as a control. Mice were monitored for paw swelling and clinical score. Histologic analysis was also performed. RESULTS: IL-10 treatment of established CIA inhibited paw swelling (P < 0.0001), as well as disease progression as defined by clinical score (P < 0.0002). Cartilage destruction, as assessed histologically, was reduced in IL-10-treated mice compared with controls (P < 0.01). CONCLUSION: IL-10 suppresses established CIA, probably by inhibiting proinflammatory cytokine production. Our results, taken together with previously reported findings, indicate a potential therapeutic role for IL-10 in RA.
OBJECTIVE:Interleukin-10 (IL-10) is a potent inhibitor of the proinflammatory cytokines, including tumor necrosis factor alpha and IL-1, which are considered important in the pathogenesis of rheumatoid arthritis (RA). The study was undertaken to establish whether IL-10 can ameliorate arthritis in the collagen-induced arthritis (CIA) model of RA. METHODS: DBA/1 mice were immunized with bovine type II collagen in adjuvant, and treated daily after disease onset with recombinant murineIL-10 or with saline as a control. Mice were monitored for paw swelling and clinical score. Histologic analysis was also performed. RESULTS:IL-10 treatment of established CIA inhibited paw swelling (P < 0.0001), as well as disease progression as defined by clinical score (P < 0.0002). Cartilage destruction, as assessed histologically, was reduced in IL-10-treated mice compared with controls (P < 0.01). CONCLUSION:IL-10 suppresses established CIA, probably by inhibiting proinflammatory cytokine production. Our results, taken together with previously reported findings, indicate a potential therapeutic role for IL-10 in RA.
Authors: Qi-Quan Huang; Robert Birkett; Renee E Koessler; Carla M Cuda; G Kenneth Haines; Jian-Ping Jin; Harris Perlman; Richard M Pope Journal: Arthritis Rheumatol Date: 2014-01 Impact factor: 10.995
Authors: Charles R Brown; Annie Y-C Lai; Steven T Callen; Victoria A Blaho; Jennifer M Hughes; William J Mitchell Journal: Infect Immun Date: 2008-09-29 Impact factor: 3.441